In vivo regulation of chromogranin A messenger ribonucleic acid in the parathyroid by 1,25-dihydroxyvitamin D: studies in normal rats and in chronic renal insufficiency.
Chromogranin-A (CgA) and PTH are the two major secretory products of the parathyroid gland. In vitro, 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3] increases CgA, but decreases PTH messenger RNA (mRNA) levels. We investigated the physiological significance of the induced changes in CgA expression by examining the effects of 1,25-(OH)2D3 on parathyroid CgA mRNA levels in vivo. Normal rats were injected with 1,25-(OH)2D3 at 48 and 24 h before blood sampling and isolation of both parathyroid glands. Parathyroid total RNA was extracted and CgA and PTH mRNA quantified by Northern blot analysis. CgA mRNA levels increased 1.6-, 3.2- and 5.6-fold, whereas PTH mRNA levels decreased by 37, 63 and 97%, respectively, with 1,25-(OH)2D3 doses of 10, 50, and 250 pmol/100 g BW. Parathyroid gland CgA expression also was examined in rats with mild chronic renal insufficiency, induced by a 5/6 nephrectomy 5 weeks earlier. Chronic renal insufficiency rats, fed normal chow, had elevated serum urea, creatinine, and PTH levels and reduced 1,25-(OH)2D3 but normal serum levels of calcium and phosphate. PTH mRNA levels were elevated 4-fold and CgA mRNA levels were 50% lower in the uremic animals. This indicates that the regulation of CgA expression in normocalcemic rats occurs at physiological 1,25-(OH)2D3 concentrations. In summary, increases and decreases in serum 1,25-(OH)2D3 levels are associated with corresponding increases and decreases in CgA mRNA levels in the parathyroid glands of rats. Therefore, this study is the first to demonstrate the physiological relevance of the earlier in vitro observations.
Soliman
E
E
Department of Medicine, McGill University and Royal Victoria Hospital, Montreal, Quebec, Canada.
Canaff
L
L
Fox
J
J
Hendy
G N
GN
D000818:Animals; D001806:Blood Urea Nitrogen; D015152:Blotting, Northern; D002117:Calcitriol / Q000097:blood / Q000494:pharmacology*; D002118:Calcium / Q000097:blood; D053379:Chromogranin A; D002864:Chromogranins / Q000096:biosynthesis*; D003404:Creatinine / Q000097:blood; D004305:Dose-Response Relationship, Drug; D007676:Kidney Failure, Chronic / Q000097:blood / Q000378:metabolism*; D008297:Male; D009392:Nephrectomy; D015345:Oligonucleotide Probes; D010280:Parathyroid Glands / Q000187:drug effects / Q000378:metabolism*; D010281:Parathyroid Hormone / Q000096:biosynthesis* / Q000097:blood; D010710:Phosphates / Q000097:blood; D012333:RNA, Messenger / Q000096:biosynthesis; D051381:Rats; D017207:Rats, Sprague-Dawley; D012016:Reference Values; D014158:Transcription, Genetic / Q000187:drug effects*; D014511:Uremia / Q000097:blood / Q000378:metabolism*
D053379:Chromogranin A; D002864:Chromogranins; D015345:Oligonucleotide Probes; D010281:Parathyroid Hormone; D010710:Phosphates; D012333:RNA, Messenger; C506153:chromogranin A, rat; D003404:Creatinine; D002117:Calcitriol; D002118:Calcium